Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Tagliabue, Elda"'
Autor:
Castagnoli L; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Corso S; Department of Oncology, University of Torino, Candiolo, Turin, Italy.; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy., Franceschini A; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Raimondi A; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Venezian 1, 20133, Milan, Italy., Bellomo SE; Department of Oncology, University of Torino, Candiolo, Turin, Italy.; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy., Dugo M; Department of Medical Oncology-Breast Cancer Unit Clinical Translational and Immunotherapy Research, IRCCS Ospedale San Raffaele, Milan, Italy., Morano F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Venezian 1, 20133, Milan, Italy., Prisciandaro M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Venezian 1, 20133, Milan, Italy., Brich S; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Belfiore A; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Vingiani A; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Di Bartolomeo M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Venezian 1, 20133, Milan, Italy., Pruneri G; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Giordano S; Department of Oncology, University of Torino, Candiolo, Turin, Italy.; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy., Pietrantonio F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Venezian 1, 20133, Milan, Italy. filippo.pietrantonio@istitutotumori.mi.it., Pupa SM; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy. serenella.pupa@istitutotumori.mi.it.
Publikováno v:
Cellular oncology (Dordrecht) [Cell Oncol (Dordr)] 2023 Jun; Vol. 46 (3), pp. 661-676. Date of Electronic Publication: 2023 Feb 08.
Autor:
Pizzamiglio S; Bioinformatics and Biostatistics Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Cosentino G; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Ciniselli CM; Bioinformatics and Biostatistics Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., De Cecco L; Integrated Biology Platform, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Cataldo A; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Plantamura I; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Triulzi T; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., El-Abed S; Breast International Group (BIG), Brussels, Belgium., Wang Y; Novartis Pharma AG, Basel, Switzerland., Bajji M; Institute Jules Bordet (IJB), Brussels, Belgium., Nuciforo P; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Huober J; Breast Center, Cantonal Hospital, St. Gallen, Switzerland., Ellard SL; BC Cancer, Kelowna, British Columbia, Canada., Rimm DL; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA., Gombos A; Institute Jules Bordet (IJB), Brussels, Belgium., Daidone MG; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Verderio P; Bioinformatics and Biostatistics Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Di Cosimo S; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Iorio MV; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Cancer medicine [Cancer Med] 2022 Jan; Vol. 11 (2), pp. 332-339. Date of Electronic Publication: 2021 Dec 17.
Autor:
Di Modica M; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Gargari G; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Regondi V; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Bonizzi A; Department of Biomedical and Clinical Sciences 'L. Sacco,' Università degli Studi di Milano, Milan, Italy., Arioli S; Department of Food, Environmental and Nutritional Sciences (DeFENS), Università degli Studi di Milano, Milan, Italy., Belmonte B; Tumor Immunology Unit, Department PROMISE, Università degli Studi di Palermo, Palermo, Italy., De Cecco L; Platform of Integrated Biology, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Fasano E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Bianchi F; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Bertolotti A; Department of Pathology, Fondazione IRCSS Istituto Nazionale Tumori, Milan, Italy., Tripodo C; Tumor Immunology Unit, Department PROMISE, Università degli Studi di Palermo, Palermo, Italy.; IFOM, the FIRC Institute of Molecular Oncology, Milan, Italy., Villani L; Pathology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy., Corsi F; Department of Biomedical and Clinical Sciences 'L. Sacco,' Università degli Studi di Milano, Milan, Italy.; Breast Unit, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy., Guglielmetti S; Department of Food, Environmental and Nutritional Sciences (DeFENS), Università degli Studi di Milano, Milan, Italy., Balsari A; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Department of Biomedical Science for Health, Università degli Studi di Milano, Milan, Italy., Triulzi T; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. elda.tagliabue@istitutotumori.mi.it.
Publikováno v:
Cancer research [Cancer Res] 2021 Apr 15; Vol. 81 (8), pp. 2195-2206. Date of Electronic Publication: 2021 Jan 22.
Autor:
Rossini A; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Giussani M; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Ripamonti F; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Aiello P; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Regondi V; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Balsari A; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.; Dipartimento Di Scienze Biomediche per La Salute, Università Degli Studi Di Milano, Milan, Italy., Triulzi T; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Publikováno v:
Cancer biology & therapy [Cancer Biol Ther] 2020 May 03; Vol. 21 (5), pp. 463-475. Date of Electronic Publication: 2020 Feb 23.
Autor:
Agnolon V; Regional Center for Biomarkers, Department of Clinical Pathology and Transfusion Medicine, Azienda ULSS 3 Serenissima, Regional Hospital, Campo SS Giovanni e Paolo 6777, 30122, Venice (VE), Italy.; Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois (CHUV), Rue du Bugnon 46, 1011, Lausanne, Switzerland., Contato A; Regional Center for Biomarkers, Department of Clinical Pathology and Transfusion Medicine, Azienda ULSS 3 Serenissima, Regional Hospital, Campo SS Giovanni e Paolo 6777, 30122, Venice (VE), Italy., Meneghello A; Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico (CRO) IRCCS, Via F. Gallini 2, 33081, Aviano (PN), Italy.; Department of Molecular Sciences and Nanosystems, Ca' Foscari University of Venice, Via Torino 155, 30172, Venezia, Italy., Tagliabue E; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133, Milan (MI), Italy., Toffoli G; Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico (CRO) IRCCS, Via F. Gallini 2, 33081, Aviano (PN), Italy., Gion M; Regional Center for Biomarkers, Department of Clinical Pathology and Transfusion Medicine, Azienda ULSS 3 Serenissima, Regional Hospital, Campo SS Giovanni e Paolo 6777, 30122, Venice (VE), Italy., Polo F; Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico (CRO) IRCCS, Via F. Gallini 2, 33081, Aviano (PN), Italy. federico.polo@unive.it.; Department of Molecular Sciences and Nanosystems, Ca' Foscari University of Venice, Via Torino 155, 30172, Venezia, Italy. federico.polo@unive.it., Fabricio ASC; Regional Center for Biomarkers, Department of Clinical Pathology and Transfusion Medicine, Azienda ULSS 3 Serenissima, Regional Hospital, Campo SS Giovanni e Paolo 6777, 30122, Venice (VE), Italy. aline.fabricio@aulss3.veneto.it.
Publikováno v:
Scientific reports [Sci Rep] 2020 Feb 20; Vol. 10 (1), pp. 3016. Date of Electronic Publication: 2020 Feb 20.
Autor:
Koschorke A; Molecular Targeting Unit, Department of Research, AmadeoLab, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Faraci S; Molecular Targeting Unit, Department of Research, AmadeoLab, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Giani D; Molecular Targeting Unit, Department of Research, AmadeoLab, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Chiodoni C; Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Iorio E; Core Facilities, NMR and MRI Unit, Istituto Superiore di Sanità, Rome, Italy., Canese R; Core Facilities, NMR and MRI Unit, Istituto Superiore di Sanità, Rome, Italy., Colombo MP; Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Lamolinara A; Department of Medicine and Aging Science, Center of Excellence on Aging and Translational Medicine (CeSi-Met), G. D'Annunzio University, Chieti-Pescara, Italy., Iezzi M; Department of Medicine and Aging Science, Center of Excellence on Aging and Translational Medicine (CeSi-Met), G. D'Annunzio University, Chieti-Pescara, Italy., Ladomery M; Faculty of Health and Applied Sciences, University of the West of England, Coldharbour Lane, Frenchay, Bristol, BS16 1QY, UK., Vernieri C; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; IFOM, FIRC Institute of Molecular Oncology, Università degli Studi di Milano, Milan, Italy., de Braud F; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy., Di Nicola M; Unit of Immunotherapy and Anticancer Innovative Therapeutics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Research, AmadeoLab, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Castagnoli L; Molecular Targeting Unit, Department of Research, AmadeoLab, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Pupa SM; Molecular Targeting Unit, Department of Research, AmadeoLab, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. serenella.pupa@istitutotumori.mi.it.
Publikováno v:
Cellular oncology (Dordrecht) [Cell Oncol (Dordr)] 2019 Dec; Vol. 42 (6), pp. 815-828. Date of Electronic Publication: 2019 Aug 02.
Autor:
Di Cosimo S; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Triulzi T; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Pizzamiglio S; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., De Cecco L; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., de Azambuja E; Istitut Jules Bordet, Universitè Libre de Bruxelles, Belgium., Fumagalli D; Breast International Group (BIG)-aisbl, Bruxelles, Belgium., Putzai L; Yale Cancer Center, Yale School of Medicine, New Haven, USA., Harbeck N; Brustzentrum der Universität München (LMU), Munchen, Germany., Izquierdo M; Oncology Clinical Development, Oncology Business Unit, Novartis Pharma AG, Basel, Switzerland., Peña L; Vall D'Hebron Institute of Oncology, Barcelona, Spain., Daidone MG; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Huober J; University of Ulm, Ulm, Germany., Gori S; IRCCS Sacro Cuore-Don Calabria Hospital, Negrar, Verona, Italy., Cinieri S; Antonio Perrino Hospital, Brindisi, Italy., Torri V; IRCCS - Istituto di Ricerche Farmacologiche 'Mario Negri' Milano, Italy., Baselga J; Vall D'Hebron Institute of Oncology, Barcelona, Spain., Piccart M; Istitut Jules Bordet, Universitè Libre de Bruxelles, Belgium., de Braud FG; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Apolone G; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Verderio P; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Tagliabue E; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Electronic address: elda.tagliabue@istitutotumori.mi.it.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2019 Sep; Vol. 118, pp. 1-9. Date of Electronic Publication: 2019 Jul 05.
Autor:
Volpi CC; Department of the Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Pietrantonio F; Department of Oncology and Hemato-oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Faculty of Medicine, Oncology and Hemato-Oncology Department, Università degli Studi di Milano, Milan, Italy., Gloghini A; Department of the Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Fucà G; Department of Oncology and Hemato-oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Giordano S; Department of Oncology, University of Turin, Turin, Italy.; Candiolo Cancer Institute, FPO - IRCCS - Candiolo (TO), Turin, Italy., Corso S; Department of Oncology, University of Turin, Turin, Italy.; Candiolo Cancer Institute, FPO - IRCCS - Candiolo (TO), Turin, Italy., Pruneri G; Department of the Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Antista M; Department of Oncology and Hemato-oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Cremolini C; Unit of Medical Oncology, Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy., Fasano E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Saggio S; Department of Oncology and Hemato-oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Faraci S; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Di Bartolomeo M; Department of Oncology and Hemato-oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., de Braud F; Department of Oncology and Hemato-oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Faculty of Medicine, Oncology and Hemato-Oncology Department, Università degli Studi di Milano, Milan, Italy., Di Nicola M; Department of Oncology and Hemato-oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Pupa SM; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. serenella.pupa@istitutotumori.mi.it., Castagnoli L; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Scientific reports [Sci Rep] 2019 Mar 05; Vol. 9 (1), pp. 3545. Date of Electronic Publication: 2019 Mar 05.
Autor:
Castagnoli L; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Iorio E; Core Facilities, NMR Unit, Istituto Superiore di Sanità, Roma, Italy., Dugo M; Functional Genomics and Bioinformatics Core Facility, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale deiTumori, Milan, Italy., Koschorke A; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Faraci S; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Canese R; Core Facilities, NMR Unit, Istituto Superiore di Sanità, Roma, Italy., Casalini P; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Nanni P; Laboratory of Immunology and Biology of Metastasis, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy., Vernieri C; IFOM, FIRC Institute of Molecular Oncology, Milan, Italy.; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Di Nicola M; Unit of Immunotherapy and Anticancer Innovative Therapeutics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Morelli D; Laboratory Medicine Unit, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Pupa SM; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Journal of cellular physiology [J Cell Physiol] 2019 Feb; Vol. 234 (2), pp. 1768-1779. Date of Electronic Publication: 2018 Aug 21.
Autor:
Triulzi T; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy., Regondi V; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy., De Cecco L; Platform of Integrated Biology, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy., Cappelletti MR; U.O. Multidisciplinare di Patologia Mammaria e Ricerca Traslazionale, Azienda Socio-Sanitaria Territoriale di Cremona, Cremona, Italy., Di Modica M; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy., Paolini B; Anatomic Pathology A Unit, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy., Lollini PL; Laboratory of Immunology and Biology of Metastases, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy., Di Cosimo S; Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy., Sfondrini L; Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Milano, Italy., Generali D; U.O. Multidisciplinare di Patologia Mammaria e Ricerca Traslazionale, Azienda Socio-Sanitaria Territoriale di Cremona, Cremona, Italy.; Dipartimento Universitario Clinico di Scienze Mediche, Chirurgiche e della Salute, Università degli Studi di Trieste, Trieste, Italy., Tagliabue E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy. elda.tagliabue@istitutotumori.mi.it.
Publikováno v:
British journal of cancer [Br J Cancer] 2018 Dec; Vol. 119 (12), pp. 1487-1494. Date of Electronic Publication: 2018 Nov 27.